Thesis (Ph. D.)--University of Oklahoma. / Bibliography: leaves 162-169.

<p>Kontaktna senzibilizacija, kao stanje specifične reaktivnosti kože, može biti egzogeni pokretač psorijaze. Rezultat je interakcije endogenih i egzogenih činioca. Jedan od najznačajnijih endogenih faktora kome se pripisuje uloga faktora rizika jeste pol. Cilj istraživanja bio je da se kod obolelih od psorijaze utvrdi učestalost i distribucija kontaktne senzibilizacije u odnosu na pol, razlike u distribuciji kontaktne senzibilizacije po polu&nbsp; između osoba obolelih od psorijaze i osoba pod sumnjom na postojanje kontaktnog alergijskog dermatitisa, povezanost kontaktne senzibilizacije i težine kliničkog nalaza i povezanost kontaktne senzibilizacije i dužine trajanja oboljenja. Hipoteza istraživanja polazila je od pretpostavke da je kontaktni alergijski dermatitis redak kod obolelih od psorijaze, jer hronična inflamacija u koži smanjuje njenu sposobnost specifične senzibilizacije a da je veća učestalost kontaktne senzibilizacije kod osoba ženskog pola rezultat egzogenog faktora tj.ekspozicije, kao i da je učestalost kontaktne senzibilizacije u pozitivnoj korelaciji sa težinom i dužinom trajanja oboljenja. Istaživanje je sprovedeno kod 176 ispitanika koji su bili podeljeni u dve grupe. Eksperimentalnu grupu su činili oboleli od psorijaze, a kontrolnu grupu ispitanici upućeni na alergolo&scaron;ko testiranje pod sumnjom na postojanje kontaktnog alergijskog dermatitisa. Obolelima od psorijaze je ocenjivana težine oboljenja PASI skorom, a svi ispitanici bili su alergolo&scaron;ki testirani epikutanim -pač testom. Pozitivni rezultati alergolo&scaron;kog testiranja su analizirani, u cilju utvrđivanja kliničke relevantnosti istih. Ispitanicima u grupi obolelih od psorijaze je testom skarifikacije određivano prisustvo ili odsustvo Koebnerovog izomorfnog podražajnog fenomena. Istraživanjem je utvrđeno, da se kontaktno reagovanje kod obolelih od psorijaze na najmanje jedan standardni alergen nije statistički značajno razlikovalo od reagovanja osoba kod kojih je postavljena sumnja na postojanje kontaktnog alergijskog dermatitisa, ali je senzitivnost izražena kroz prosečan broj pozitivnih testova po jednom ispitaniku bila statistički značajno niža kod obolelih od psorijaze. Poređenjem kontaktnog reagovanja mu&scaron;karaca i žena nisu utvrđene značajna razlike u reagovanju u odnosu na pol. Težina oboljenja nije uticala na učestalost kontaktne senzibilizacije kod obolelih od psorijaze, ali je učestalost kontaktne senzibilizacije bila u pozitivnoj korelaciji sa dužinom trajanja bolesti. Niža stopa kontaktnog reagovanja utvrđena je kod osoba obolelih od psorijaze koji su imali pozitivan Koebnerov fenomen u trenutku ispitivanja.</p> / <p>Contact sensitization as a state of specific skin reactivity may provoke psoriasis resulting from an interaction between extrinsic and intrinsic factors. One of the most significant factors characterized, as a risk factor, is the sex. The aim of this study was to determinate the frequency and distribution of contact sensitization in patients with&nbsp; psoriasis with respect to their sex, as well as the differences in the distribution of contact sensitization in both sexes, namely&nbsp; with patients with psoriasis and patients&nbsp; suspected to allergic contact dermatitis. Consequently, appropriate attention was paid to the correlation between contact sensitization and disease severity, and between contact sensitization and disease duration. Hypothesis were based on the assumption that allergic contact dermatitis is rare in&nbsp; patients with psoriasis, as a chronic inflammation of the skin reduces its ability specific sensitization, as well as that the higher frequency of contact sensitization in females represent a result of exogenous factors, i.e. exposition, and finally that there is a positive correlation between the incidence of contact sensitization and the disease severity, and contact sensitization and the disease duration. The study included 176 patients. They were divided into two groups: the study group included patients with psoriasis, while the control group included patients referred for allergy testing, since they were suspected to allergic contact dermatitis. The severity of psoriasis was evaluated by PASI score. Thereafter,&nbsp; each patient underwent patch testing. The positive results of patch tests were evaluated with the aim to define their clinical relevancy. Subjects from the group of psoriatic patients passed scarification test carried out to indicate the presence or absence of K&ouml;ebner isomorphic phenomenon. This research led us to the conclusion that the positive reaction of psoriatic patients to at least one standard allergen did not indicate a statistically significant different reaction when compared to the reaction of patients suspected to allergic contact dermatitis. From the other side, the sensitivity expressed through the average number of positive&nbsp; tests per one&nbsp; tested&nbsp; patients was&nbsp; significantly lower in&nbsp; patients&nbsp; with psoriasis. Comparison of the contact response of men and women showed no significant differences in response with respect to&nbsp; their sex. The&nbsp; disease severity did not influence the frequency of contact sensitization in patients&nbsp; with&nbsp; psoriasis. At&nbsp; the same time, the frequency of contact sensitization stood in a positive correlation with the duration of disease. The lower rate of contact sensitization was found in patients with psoriasis who have had a&nbsp; positive K&ouml;ebner phenomenon at&nbsp; the time of testing.</p>

Objectives: To date little is known of the interaction between diabetes and sex hormones in the vasculature. A number of studies suggest that premenopausal diabetic women loose their gender based cardiovascular protection. However, there is insufficient evidence to explain the mechanism underlying the loss of this gender based cardioprotection in premenopausal diabetic women. The objectives of this study were to investigate whether there is a gender difference in the aortic endothelial function in · streptozotocin (STZ, 58 mg/kg, iv)-induced diabetic rats, and the potential role of superoxide and cyclooxygenase (COX) metabolites in diabetes-induced vascular dysfunction.

Yes / The NHS spends billions of pounds annually on repeat prescriptions in primary care, but data on their extent and use is out of date. Understanding the scale of repeat prescribing and for whom it is prescribed is important for the NHS to plan services and develop policies to improve patient care. Anonymous data on prescription numbers and practice population demographics was obtained from GP computer systems in a large urban area.Searches were conducted in November 2011 to identify the numbers of repeat items listed on individuals' repeat lists by sex and age.The proportion of all prescription items issued as repeats was identified by conducting searches on items issued as repeat and acute prescriptions. In the year of study 4,453,225 items were issued of which 3,444,769 (77%) were repeats (mean 13 items per patient/annum) and 1,008,456 (23%) acute prescriptions (mean 3.9 items per patient per annum). The mean number of repeat Items per patient was 1.87 (range 0.45 ages 0-9 years; 7.1 ages 80-89 years). At least one repeat medicine was prescribed to 43% of the population (range 20% for ages 0-9; over 75% for ages 60+). A significant proportion of the population receive repeat prescriptions and the proportion increases with age. Whilst the proportion of repeat items to acute items has remained unchanged over the last two decades the number of repeat prescriptions items issued has doubled (from 5.8 to 13.3 items/patient/annum). This has implications for general practice workload, patient convenience, NHS costs and risk.

by Chan Kwai Foon May. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2000. / Includes bibliographical references (leaves 103-114). / Abstracts in English and Chinese. / Declaration --- p.2 / Abstract --- p.3 / Abstract in Chinese --- p.6 / Acknowledgements --- p.8 / Chapter Chapter 1. --- Introduction --- p.15 / Chapter Chapter 2. --- Osteoporosis : The relationship between aging and skeletal organization between men and women --- p.17 / Chapter 2.1. --- Skeletal organization --- p.17 / Chapter 2.1.1. --- Bone structure --- p.17 / Chapter 2.1.2. --- Bone metabolism --- p.17 / Chapter 2.1.3. --- Peak bone mass --- p.18 / Chapter 2.2. --- Bone loss between men and women --- p.20 / Chapter 2.2.1. --- Aging and bone loss --- p.20 / Chapter 2.2.2. --- Clinical aspects of bone loss in men and women --- p.21 / Chapter Chapter 3. --- Vertebral deformity : Bone Mineral Density and Body Composition --- p.23 / Chapter 3.1. --- Bone mineral density --- p.23 / Chapter 3.1.1. --- Types of vertebral deformity --- p.23 / Chapter 3.1.2. --- Clinical diagnosis in vertebral deformity --- p.24 / Chapter 3.1.3. --- Bone mineral density measurements --- p.25 / Chapter 3.1.4. --- Vertebral deformity and bone mineral density --- p.28 / Chapter 3.2. --- Bone composition --- p.33 / Chapter Chapter 4. --- Literature Review on Health Consequences of Vertebral Deformity --- p.36 / Chapter 4.1. --- Back pain --- p.36 / Chapter 4.1.1. --- Back pain and vertebral deformity --- p.36 / Chapter 4.1.2. --- Back pain in men and women with vertebral deformity --- p.38 / Chapter 4.2. --- Morale and functional limitation and vertebral deformities --- p.39 / Chapter 4.2.1. --- Function evaluation : The Barthel Index --- p.40 / Chapter 4.2.2. --- Philadelphia Geriatric Morale Scale --- p.41 / Chapter Chapter 5. --- Objectives --- p.43 / Chapter Chapter 6. --- "Subjects and methods for phase I: anthropometric measurement, body composition and bone mineral density measurement in vertebral deformity patients and controls" --- p.44 / Chapter 6.1. --- Study subjects --- p.44 / Chapter 6.2. --- Radiology and digitization protocol for diagnosis vertebral deformity --- p.46 / Chapter 6.3. --- Diagnosis of vertebral deformity --- p.48 / Chapter 6.4. --- Body composition and bone mineral density measurements --- p.54 / Chapter 6.4.1. --- Body composition analysis --- p.54 / Chapter 6.4.2. --- Lumbar spine and hip bone mineral analysis --- p.54 / Chapter 6.5. --- Quality control --- p.56 / Chapter 6.5.1. --- Routine quality control of measurements --- p.56 / Chapter 6.5.2. --- Precision on patient repositioning --- p.56 / Chapter Chapter 7. --- Subjects and methods for phase II: health consequences of vertebral deformity patients and controls --- p.57 / Chapter 7.1. --- Questionnaire on health consequences --- p.57 / Chapter 7.1.1 --- Back pain and disability --- p.57 / Chapter 7.1.2 --- Activities of daily living --- p.59 / Chapter 7.1.3 --- Morale --- p.59 / Chapter 7.2. --- Statistical methods --- p.60 / Chapter 7.2.1. --- Bone mineral density and body composition --- p.60 / Chapter 7.2.2. --- Back pain and disability --- p.60 / Chapter 7.2.3. --- Activities of daily living and morale --- p.61 / Chapter Chapter 8. --- "Results for phase I: anthropometric measurement, body composition and bone mineral density measurement in vertebral deformity patients and controls" --- p.62 / Chapter 8.1. --- Demographic characteristics of study population --- p.62 / Chapter 8.2. --- Anthropometric measurements : Body composition and bone mineral density --- p.64 / Chapter Chapter 9. --- Results for phase II: Health Consequences of vertebral deformity patients and control --- p.76 / Chapter 9.1. --- Back pain --- p.76 / Chapter 9.2. --- Disability --- p.78 / Chapter 9.3. --- Activities of daily living --- p.81 / Chapter 9.4. --- Morale --- p.82 / Chapter Chapter 10. --- Discussion I --- p.83 / Chapter 10.1. --- Study Sample --- p.83 / Chapter 10.2. --- Digitization method and definition of vertebral deformity --- p.84 / Chapter 10.3. --- Methods for bone mineral density measurement --- p.87 / Chapter 10.4. --- Questionnaire validity --- p.88 / Chapter 10.4.1. --- Back pain and disability --- p.88 / Chapter 10.4.2. --- Barthel Index --- p.88 / Chapter 10.4.3. --- Philadelphia Geriatric Morale Scale --- p.89 / Chapter Chapter 11. --- Discussion II --- p.92 / Chapter 11.1 . --- Body composition and bone mineral density --- p.92 / Chapter 11.2. --- Differences of vertebral deformity between Chinese men and Caucasian men --- p.93 / Chapter 11.3. --- Health consequences in Chinese men --- p.96 / Chapter 11.4. --- Comparison of health consequences between Chinese men and Caucasian men --- p.98 / Chapter 11.5. --- Variation of health consequences between Chinese men and Chinese women --- p.101 / Chapter 11.5.1. --- Back pain and disability --- p.101 / Chapter 11.5.2. --- Morale --- p.102 / Chapter Chapter 12. --- Conclusion --- p.103 / Reference --- p.104 / Appendix I --- p.115 / Appendix II Publication

Diss. (sammanfattning) Umeå : Umeå universitet, 2009. / Härtill 4 uppsatser.

Diss. (sammanfattning) Linköping : Univ., 2002. / Härtill 5 uppsatser.

Diss. (sammanfattning) Stockholm : Karol. inst., 2003. / Härtill 4 uppsatser.

Made available in DSpace on 2015-07-22T20:49:58Z (GMT). No. of bitstreams: 0 Previous issue date: 2011-06-29 / A redução no tempo de sono caracteriza a sociedade moderna. A associação recíproca entre a duração do sono e o ganho de peso tem sido atualmente explorada. Contudo, as conseqüências desses fatores no sistema cardiovascular permanecem não completamente elucidadas, principalmente quando verificadas ao longo da vida. Além disso, as conseqüências da privação de sono ainda podem sofrer a influência do fator sexo. Assim, o objetivo do presente estudo foi verificar o impacto da privação de sono aguda associada à obesidade em ratas Zucker de diferentes idades (Artigo 1) e comparar os efeitos da privação de sono paradoxal (PSP) e restrição de sono (RS) crônica em ratos eutróficos machos e fêmeas (Artigo 2) nos parâmetros cardiovasculares (Artigos 1 e 2) e hormonal (Artigo 2). Para a realização do Artigo 1, ratas Zucker fêmeas magras e obesas de 3, 6 e 15 meses de idade foram distribuídas em grupos controle (CTRL, gaiolas-moradia) ou privação de sono (PS). Para o Artigo 2, ratos adultos machos e fêmeas da linhagem Wistar foram distribuídos nos grupos: controle (CTRL, gaiolas-moradia), PSP (ratos submetidos a PSP por 96 horas) ou RS (ratos submetidos à RS por 21 dias). Para ambos os artigos, os animais foram anestesiados após respectivo protocolo de PS ou tempo equivalente nos grupos CTRL, para cateterização da artéria e veia femorais. Em seguida, o índice de sensibilidade baroreflexa foi mensurado por infusões de fenilefrina (resposta bradicárdica) e nitroprussiato de sódio (resposta taquicárdica). No caso do Artigo 2, outro grupo de animais foi utilizado para a coleta sanguínea a fim de avaliar as concentrações de hormônio adrenocorticotrófico (ACTH). No Artigo 1, observamos que a obesidade resultou em disfunção da resposta taquicárdica nos animais desde os 3 meses de idade. Aos 6 e 15 meses de idade, a resposta bradicárdica e taquicárdica foram significativamente menores em animais obesos comparados aos respectivos grupos magros. Aos 15 meses de idade, a interação entre obesidade, PS e idade provocou as maiores conseqüências no sistema cardiovascular, uma vez que aumentou a pressão arterial, a freqüência cardíaca e reduziu a sensibilidade baroreflexa. No Artigo 2, os resultados mostraram que a pressão arterial média foi significativamente maior no grupo RS comparada ao grupo CTRL em ambos os sexos. Em fêmeas, a freqüência cardíaca foi significativamente maior após a PSP comparada ao respectivo grupo CTRL. O protocolo de RS atenuou a resposta baroreflexa vagal similarmente em ratos machos e fêmeas. A resposta baroreflexa simpática foi atenuada nos grupos PSP e RS, contudo, em fêmeas este parâmetro foi afetado apenas após o procedimento de PSP. Nenhuma diferença significativa em relação ao sexo foi observada para qualquer parâmetro cardiovascular em ratos da linhagem Wistar, apenas a PSP aumentou significativamente as concentrações de ACTH comparado ao grupo CTRL em ambos os sexos. Em conjunto, esses resultados sugerem que diferentes durações de perda de sono levam a conseqüências específicas nos parâmetros cardiovasculares e hormonais e estes efeitos foram similares entre ratos machos e fêmeas no caso de ratos eutróficos. Em animais obesos, a associação entre os fatores de risco (obesidade, PS e idade) exerceram as piores consequências nos parâmetros cardiovasculares analisados. / Curtailment of sleep time is a characteristic of modern society, and the reciprocal association between duration of sleep and weight gain has been under scrutiny as of late. The consequences of such factors upon the cardiovascular system remain to be fully elucidated, particularly along a full life span. Moreover, the consequences of sleep deprivation may also be influenced by the gender. The current study thus purported to examine the impact of acute sleep deprivation associated to obesity in female Zucker rats of different ages (Paper 1) and to compare the effects of paradoxical sleep deprivation (PSD) and chronic sleep restriction (SR) in male and female eutrophic rats (Paper 2) upon the cardiovascular (Papers 1 and 2) and hormonal (Paper 2 ) parameters. For the experiments described in Paper 1 lean and obese female Zucker rats 3, 6, and 15 months old were distributed into either control groups (CTRL, homecage) or sleep deprived (SD). For the experiments of Paper 2 adult female and male Wistar rats were distributed in either control groups (CTRL, home-cage) or in Paradoxical Sleep Deprivation for 96h groups (PSD-96h) or Sleep Restriction for 21 days groups (SR 21 days). In both experiments the subjects were anesthetized according to respective SD protocol or equivalent time in the CTRL groups, after which a catheter was placed in their femoral artery and vein. The baroreflex sensibility index was measured by means of phenilephrine (bradicardiac response) and sodium nitroprussiate (taquicardiac response). For the experiments conducted for Paper 2 a different group of subjects was used for blood harvesting to assess the concentrations of adrenocorticotrophic hormone (ACTH). In Paper 1 we observed that obesity resulted in dysfunctional taquicardia in subjects from 3 months of age and on. At 6 and 15 months of age the bradicardiac and taquicardiac response were significantly smaller in obese subjects when compared to respective lean groups. At 15 months of age the interaction between obesity, SD and age caused the greatest consequences in the cardiovascular system as arterial. Results of Paper 2 show that the average arterial pressure was significantly higher in the SR group when compared to the CTRL group in both genders. In females, cardiac frequency was significantly higher after PSD when compared to respective controls. The SR protocol attenuated the vagal baroreflex response similarly in males and females. The sympathetic baroreflex response was attenuated in the PSD and SR groups, but in females this parameter was affected only after PSD. No significant difference in relation to gender was observed in any of the cardiovascular parameters. PSD did increase ACTH concentrations significantly when compared to controls of both genders. The body of results yielded by both studies suggests that different periods of lost sleep lead to specific consequences in cardiovascular and hormonal parameters, and such effects were similar in male and female rat subjects. / TEDE

<p>&Scaron;irom sveta, karcinom bronha je i dalje vodeći po incidenci i mortalitetu, sa 2,1 milion novih slučajeva i predviđenih 1,8 smrtnih ishoda u 2018. godini. Karcinom bronha predstavlja skoro petinu (18,4%) svih smrtnih ishoda od karcinoma. Istraživanje je sprovedeno kao retrospektivna studija za period 2010-2016 godine. Svi podaci potrebni za sprovođenje ovog istraživanja direktno su prikupljeni iz zdravstvenog informacionog sistema i registra za karcinom bronha Instituta za plućne bolesti Vojvodine (IPBV), koji je referentna ustanova za pacijente sa karcinomom bronha za celu Autonomnu Pokrajinu Vojvodinu. Cilj rada je bio da se utvrdi uticaj demografskih i kliničko-patololo&scaron;kih karakteristika na ukupno vreme preživljavanja kod bolesnika sa karcinomom bronha, kao i da se izradi geoprostorna analiza incidencije i mortaliteta od karcinoma bronha na teritoriji Vojvodine. Podaci o broju novoobolelih i broju umrlih pacijenata potrebni za analizu incidencije i mortaliteta prikupljeni su od lokalnih Instituta za javno zdravlje za svaki od sedam okruga. Za potrebe analize overall survivall, survival rate ukupno je obuhvaćeno 8142 bolesnika lečenih u IPBV, od kojih je nakon provere uključujućih i isključujućih kriterijuma, u konačnu analizu u&scaron;lo njih 7540. Za potrebe analize incidencije i mortaliteta prikupljeni su podaci od lokalnih Instituta za javno zdravlje za svaki od sedam okruga i ukupno je uključeno 21915 pacijenata. Od ukupno 7540 bolesnika, bilo je 5456 (72,4%) mu&scaron;karaca i 2084 (27,6%) žena. Prosečna starost bolesnika iznosila je 63,4&plusmn;8,85 godina, Najveći broj bolesnika su bili pu&scaron;ači, njih 4911 (65,1%), biv&scaron;ih pu&scaron;ača je bilo 1995 (26,5%), dok je najmanje bilo nepu&scaron;ača, svega 634 (8,4%). Srednja vrednost indeksa paklo-godina (pack-years) iznosila je 50,57&plusmn;28,80. Posmatrano prema bračnom statusu, najvi&scaron;e bolesnika je bilo oženjeno/udato, njih 5348 (70,9%). Najveći broj bolesnika je ocenio svoj socioekonomski status kao osrednji, njih 4912 (65,1%). Broj bolesnika sa ECOG performans statusom 1 bio je 5679 (75,3%), njih 840 (11,1%) je imalo ECOG performans status 2, dok je ECOG performans status 0 imao 451 (6,0%) bolesnik. Najveći broj bolesnika bio je dijagnostikovan u IV stadijumu bolesti 3108 (41,2%), zatim u IIIB 1886 (25,0%), IIIA 1401 (18,6%), dok je u IA stadijumu dijagnostikovano najmanje bolesnika, njih 234 (3,1%). Najveći broj bolesnika imao je potvrđenu dijagnozu adenokarcinoma, njih 3342 (44,3%), zatim skvamoznog karcinoma 2472 (32,8%), mikrocelularnog karcinoma 1386 (18,4%). Od ukupnog broja bolesnika, tokom perioda praćenja preminulo je njih 6420 (85,1%), dok je 1120 (14,9%) bolesnika bilo živo. Prosečno vreme preživljavanja mu&scaron;karaca bilo je 17,116 meseci, a žena 23,193 meseca. Mu&scaron;karci oboleli od karcinoma bronha statistički značajno (p=0,000) kraće su živeli u odnosu na žene. Analiza kumulativnog preživljavanja bolesnika pokazala je da je postojala statistički značajna razlika u preživljavanju u odnosu na pol kod podtipova adenokarcinom (p=0,000), skvamozni karcinom (p=0,000) i mikrocelularni karcinom (p=0,001). Statistički značajna razlika u preživljavanju postojala je i u odnosu na starost, mesto stanovanja, tip tumora, stadijum bolesti, ECOG, pu&scaron;ački status i TNM stadijum bolesti (p=0,000). Ukupno jednogodi&scaron;nje preživljavanje obolelih od karcinoma bronha iznosilo je 32,5%, skvamoznog karcinoma 37,3%, adenokarcinoma 33,4% i mikrocelularnog karcinoma 20,9%. Ukupno trogodi&scaron;nje preživljavanje obolelih od karcinoma bronha iznosilo je 9,2%, skvamoznog karcinoma 10,8%, adenokarcinoma 10,7% i mikrocelularnog karcinoma 2,0%. Ukupno petogodi&scaron;nje preživljavanje obolelih od karcinoma bronha iznosilo je 5,0%, kod skvamoznog karcinoma 6,1%, adenokarcinoma 5,4% i mikrocelularnog karcinoma 1,3%. Ukupno jednogodi&scaron;nje preživljavanje obolelih od karcinoma bronha u 1A stadijumu iznosilo je 78,1%, u 1B stadijumu 73,2%, 2A stadijumu 70,4%, 2B stadijumu 52,1%, 3A stadijumu 42,3%, 3B stadijumu 28,3%, dok je u 4 stadijumu bolesti ukupno jednogodi&scaron;nje preživljavanje bilo 17,9%. Ukupno trogodi&scaron;nje preživljavanje obolelih od karcinoma bronha u 1A stadijumu iznosilo je 40,8%, u 1B stadijumu 37,5%, 2A stadijumu 31,2%, 2B stadijumu 21,6%, 3A stadijumu 9,7%, 3B stadijumu 5,5%, dok je u 4 stadijumu bolesti ukupno trogodi&scaron;nje preživljavanje bilo 2,9%. Ukupno petogodi&scaron;nje preživljavanje obolelih od karcinoma bronha u 1A stadijumu iznosilo je 32,1%, u 1B stadijumu 19,3%, 2A stadijumu 16,2%, 2B stadijumu 13,3%, 3A stadijumu 4,4%, 3B stadijumu 2,6%, dok je u 4 stadijumu bolesti ukupno petogodi&scaron;nje preživljavanje bilo 1,6%. Kao nezavisni prediktori preživljavanja izdvojeni su mu&scaron;ki pol, starost preko 60 godina, ECOG performans status veći od 2, pu&scaron;ačka navika, lo&scaron;iji socioekonomski status, stadijum IV bolesti, T4 status, M1b status i mikrokarcinom kao tip tumora (p=0,000). Incidencija karcinoma bronha za mu&scaron;karce iznosila je 118,9 na 100000 stanovnika, a za žene 43,3 na 100000 stanovnika. Standardizovana stopa incidencije karcinoma bronha za mu&scaron;karce iznosila je 65,4 na 100000 stanovnika, a za žene 21,7 na 100000 stanovnika. Prema okruzima je postojala statistički značajna razlika (p=0,001). Stopa mortaliteta od karcinoma bronha za mu&scaron;karce iznosila 125,1 na 100000 stanovnika, a za žene 43,8 na 100000 stanovnika. Standardizovana stopa mortaliteta od karcinoma bronha za mu&scaron;karce iznosila 67,6 na 100000 stanovnika, a za žene 20,9 na 100000 stanovnika. Prema okruzima je postojala statistički značajna razlika (p=0,001). Analizom prikupljenih podataka utvrđeno je da postoji statistički značajna razlika u ukupnom vremenu preživljavanja pacijenata sa dijagnostikovanim karcinomom bronha u odnosu na pol (p=0,000), starosnu dob (p=0,000), mesto stanovanja (p=0,014), pu&scaron;ački status (p=0,001), ECOG performans status (p=0,000) i socioekonosmski status (p=0,000). Postoji statistički značajna razlika u ukupnom vremenu preživljavanja pacijenata sa dijagnostikovanim karcinomom bronha u odsnosu na tip tumora (p=0,000), stadijum bolesti (p=0,000), T-deskriptor (p=0,000), N-deskriptor (p=0,000) i M-deskriptor (p=0,000). Utvrđeno je da ukupno jednogodi&scaron;nje preživljavanje obolelih od karcinoma bronha iznosi 32,5%, trogodi&scaron;nje preživljavanje obolelih od karcinoma bronha iznosi 9,2%, a petogodi&scaron;nje preživljavanje iznosi 5,0%. Utvrđeno je da su nezavisni prediktori preživljavanja mu&scaron;ki pol, starost preko 60 godina, ECOG performans status 2 i veći, pu&scaron;ačka navika, lo&scaron;iji socioekonomski status, stadijum IV bolesti, T4 status, M1b status i mikroculularni karcinom kao tip tumora. Urađena je analiza incidencije i mortaliteta od karcinoma bronha na teritoriji AP Vojvodine i utvrđeno je da postoje značajne regionalne razlike u incidenciji i mortalitetu od karcinoma bronha na teritoriji AP Vojvodine.</p> / <p>Worldwide, lung cancer remains the leading cause of cancer incidencije and mortality, with 2.1 million new lung cancer cases and 1.8 million deaths predicted in 2018. Methodology: For the purpose of this retrospective study we collected data of 21915 patients from seven Public Health Institutes, one for each district. This data was categorized by five-year age groups during 2010&ndash;2016. Survival analysis data of 8142 patients was collected from the Institute for Pulmonary Diseases of Vojvodina Hospital Information System and the Lung Cancer Registry. The primary objective was to determine the impact on overall survival by assessing demographic and clinical pathological characteristics in these patients. The secondary objective was to analyze the incidencije and mortality of lung cancer in the region of Vojvodina. Incidencije and mortality rates were directly age-standardized to the World and Europe Standard Population. A total of 7540 patients were eligible for the survival analysis, 5456 (72.4%) males and 2084 (27.6%) females. The average survival time, including all stages and cancer types was 17.1 months for men and 23.2 months for women (p = 0.000). There was statistically significant difference in survival time by gender in subtypes of adenocarcinoma (p = 0.000), squamous cell carcinoma (p= 0.000) and microcellular carcinoma (p = 0.001). Analysis showed significant difference in survival by age (p = 0.000), cancer type (p = 0.000), stage of the disease (p = 0.000), ECOG performance status (p = 0.000), smoking status (p = 0.001), TNM stage of disease (p = 0.000) and among districts (p = 0.014). Male gender (p = 0.000), age over 60 (p = 0.000), ECOG performance status 2 and greater (p = 0.000), smoking habit (p = 0.002), lower socioeconomic status (p = 0.000), stage IV of disease (p = 0.000) and small cell lung cancer as tumor type (p = 0.000) were identified as independent prognostic factors. One-year survival in 1A stage was 78.1%, in 1B stage 73.2%, 2A stage 70.4%, 2B stage 52.1%, 3A stage 42.3%, 3B stage 28.3 %, while in stage 4 was 17.9%. Three-year survival in 1A stage was 40.8%, in 1B stage 37.5%, 2A stage 31.2%, 2B stage 21.6%, 3A stage 9.7%, 3B stage 5.5 %, while in stage 4 was 2.9%. Five-year in 1A stage is 32.1%, in 1B stage 19.3%, 2A stage 16.2%, 2B stage 13.3%, 3A stage 4.4%, 3B stage 2.6 %, while in stage 4 was 1.6%. The incidencije rate was 118.9 per 100000 for males and 43.3 per 100000 for women. The standardized incidencije rate was 65.4 per 100000 for males and 21.7 per 100000 for females. There was a statistically significant difference by districts (p = 0.001). Mortality rate was 125.1 per 100000 for males and 43.8 per 100000 for females. The standardized mortality rate was 67.6 per 100000 for males and 20.9 per 100000 for females. There was also a statistically significant difference by district (p = 0.001). There was a statistically significant difference in overall survival by gender (p = 0.000), age (p = 0.000), place of residence (p = 0.014), smoking status (p = 0.001), ECOG performance status (p = 0.000), and socioeconomic status (p = 0.000). There was also a statistically significant difference in the overall survival by tumor type (p = 0.000), stage of disease (p = 0.000), T-descriptor (p = 0.000), N-descriptor (p = 0.000), and M-descriptor (p = 0.000). One-year survival rate was 32.5%, three-year survival was 9.2%, and five-year survival rate was 5.0%. Incidencije and mortality rates data were analyzed for the territory of Vojvodina, and it was found that there were significant regional differences.</p>